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Upon reading Christopher Good-
now’s recent Review article in Cell, 
which emphasized the overlapping 
role of somatic mutation in autoim-
munity and cancer (Goodnow, 2007), 
I was reminded of a graduate lecture 
course given by Professor Roderick 
MacLeod in 1995 at the University of 
Illinois. While introducing F.M. Bur-
net’s clonal selection theory to our 
small class, Professor MacLeod men-
tioned Burnet’s idea that germline 
and somatic mutations provide the 
inherited and stochastic mechanisms 
that disrupt tolerance and result in 
autoimmunity. In his Review article, 
Goodnow independently derives and 
extends this idea using compelling 
examples from more than 30 years 
of molecular and cellular immunology 
research that has accumulated since 
Burnet’s insight. However, I recall 
during our class discussion that we 
did not find the potential impact of 
somatic mutation entirely satisfying. 
Three issues arose: sex, aging, and 
epitope spreading.
Autoimmune diseases commonly 
afflict the young and middle-aged. 
In contrast, the most significant risk 
factor for cancer is increasing age. 
According to the Surveillance Epide-
miology and End Results (SEER) data-
base, an analysis of data from 2000 
to 2004 revealed that the median age 
for developing cancer in the United 
States is 67 years (Ries et al., 2007). 
If the accumulation of somatic muta-
tions is a major factor for develop-
ing autoimmunity, one would expect 
a similar median age of onset for 
autoimmune disease. One explana-
tion for this apparent discrepancy is 
the reduction in lymphocyte produc-
tion by the bone marrow and thymus 
as we enter middle age (Linton and 
Dorshkind, 2004). This reduction in 
naive and potentially self-reactive 
lymphocytes could lead to substan-
tially fewer opportunities for self-
reactive rogue lymphocyte clones 
to arise due to somatic mutation in 1220 Cell 131, December 28, 2007 ©2007later life, subsequently reducing the 
incidence of autoimmune disease in 
older age groups (which Burnet also 
postulated; Burnet, 1972). On the 
other hand, a recent summary of the 
median age of onset for autoimmune 
disease suggests that at least some 
autoimmune diseases have an older 
age of onset (>50 years) than previ-
ously thought (Cooper and Stroehla, 
2003). Somatic mutation may play a 
greater role in the pathogenesis of 
these autoimmune diseases.
Another confounding issue is the 
higher incidence of autoimmune dis-
eases in females. There is no sub-
stantial evidence to suggest that 
the somatic mutation rate is greater 
in females. Instead, women appear 
to develop more robust immune 
responses compared to men; and 
animal models have shown that sex 
steroids affect the immune system 
and contribute to the development 
of autoimmunity (Whitacre, 2001). 
Given that the regulation of sex ste-
roid production is principally dic-
tated by the X and Y chromosomes, 
the observed sex bias for autoim-
mune disease could be considered 
the result of this more basic genetic 
predisposition to be male or female, 
rather than the result of germline or 
somatic mutations.
Somatic mutations also do not 
readily explain epitope spreading 
in autoimmune diseases. Epitope 
spreading refers to the diversifica-
tion of the immune response from a 
single epitope to multiple epitopes, 
found either on the same self-antigen 
or related self-antigens. Although dif-
ficult to observe in humans, animal 
models clearly show epitope spread-
ing during the onset of autoimmune 
disease (Vanderlugt and Miller, 2002). 
It seems unlikely that random somatic 
mutations would result in the sequen-
tial development of multiple rogue 
lymphocyte clones specific for dif-
ferent epitopes from the same target 
cell, as observed in animal models of  Elsevier Inc.autoimmune disease. One explana-
tion is that a single rogue clone could 
initiate tissue damage releasing cryp-
tic epitopes that are normally “hid-
den” from the immune system and for 
which tolerance is not established. 
Subsequent self-reactive clones spe-
cific for these cryptic epitopes would 
become active due to the local inflam-
matory milieu and would not neces-
sarily require somatic mutations to 
avoid the immune system’s mecha-
nisms for maintaining self-tolerance. 
Furthermore, one recent study has 
demonstrated the hierarchical nature 
of the epitopes that precipitate auto-
immune diabetes (Krishnamurthy et 
al., 2006). If this is the case for other 
autoimmune diseases, then a rogue 
lymphocyte must recognize the pri-
mary self-antigen before epitope 
spreading can occur. This criterion 
would significantly reduce the pool of 
potential lymphocytes that could be 
affected by somatic mutations and 
that could initiate autoimmune dis-
ease. Notwithstanding, once the pri-
mary self-antigen is recognized and 
pathogenesis begins, then somatic 
mutations could lead to enhanced 
epitope spreading and the exacerba-
tion of autoimmunity.
Finally, our class did not discuss 
infectious diseases, but in hind-
sight this point also could have been 
raised. It has been observed that the 
incidence of autoimmune diseases 
is escalating in developed coun-
tries (Bach, 2002). It is doubtful that 
this escalation would be due to an 
increase in germline and/or somatic 
mutations within these populations. 
Rather, the parallel reduction in the 
incidence of infectious diseases in 
these countries may provide an alter-
native explanation. Although hotly 
debated, the hygiene hypothesis sug-
gests that infections are beneficial for 
tempering the immune system and 
for preventing autoimmune disease 
(Bach, 2002). Childhood infection 
may provide a stochastic protective 
mechanism in those individuals who 
have inherited alleles that predispose 
them to developing autoimmune dis-
ease. This of course does not rule 
out somatic mutation as a stochastic 
causative mechanism, but stimulation 
of the regulatory immune network 
due to infection may enhance periph-
eral tolerance when somatic muta-
tions eventually give rise to rogue 
lymphocytes (Singh, 2000). It is ironic 
that elimination of infectious diseases 
might leave the immune system free 
to attack the body. Therapies that 
stimulate the regulatory network dur-
ing childhood, similar to vaccines that 
prevent infection, may enhance toler-
ance and prove more beneficial than 
targeting the elimination of rogue 
lymphocytes using pathway-specific 
drugs later in life.
None of these issues excludes 
the potential role of somatic muta-
tion in the pathogenesis of autoim-
mune disease. Yet they do suggest 
that the impact of somatic mutations 
depends heavily on the interplay of 
other factors. It is curious that an 
increase in autoimmune diseases 
has not yet been observed for popu-
lations at-risk for increased somatic 
mutations due to radiation exposure 
from atomic bombs or nuclear reac-
tor disasters (such as Hiroshima, 
Nagasaki, and Chernobyl; Imaizumi et al., 2006; Tronko et al., 2006). As 
Burnet pointed out 35 years ago, 
“No biological phenomenon can 
ever be completely, or even ade-
quately, described. There can, at 
best, only be a progressive improve-
ment in the… practical usefulness 
of the working generalizations that 
can be produced” (Burnet, 1972). In 
this regard, Goodnow’s informative 
Review article revives a very useful 
concept that will hopefully generate 
new ideas and discussion not just in 
the laboratory and clinic, but also in 
the classroom.
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